First Randomized Study To Evaluate IMLYGIC ® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Results Demonstrated a Doubling of Objective Response Rate Compared to Ipilimumab Alone in Unresectable Advanced Melanoma
Responses Were Not Limited to Injected Lesions and Favored the Combination Arm Across Subsets of Disease
THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective response rate (ORR), demonstrating that IMLYGIC in combination with YERVOY® (ipilimumab) more than doubled ORR, defined as t...
Source: Amgen News Release - October 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
Companies to Jointly Develop T-Cell Engaging Bispecific Probody
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. Probody T-cell engaging bispecifics are antibody constructs capable of directing cytotoxic T-cells in tum...
Source: Amgen News Release - October 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA ™
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018
THOUSAND OAKS, Calif., Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, and AMJEVITA in the Unit...
Source: Amgen News Release - September 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
THOUSAND OAKS, Calif. and NANJING, China, Sept. 26, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology.
Under the terms of the agreement, Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the...
Source: Amgen News Release - September 26, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Provides Update On Hurricane Maria
No Interruption to Patient Supply Anticipated
Company Reaffirms 2017 Financial Guidance
THOUSAND OAKS, Calif., Sept. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update on Hurricane Maria's impact on the Company's manufacturing facilities in Puerto Rico. The safety of the more than 2,000 Amgen colleagues and their families on the island remains a top priority for Amgen, and outreach to impacted staff is ongoing.
"The Company's preliminary assessment is that the critical manufacturing areas in our facility in Juncos, Puerto Rico, have not been significantly impacted by this storm," said Est...
Source: Amgen News Release - September 25, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts
Amgen Foundation Pledges $3 Million for Urgent Relief Efforts
Amgen Foundation Also Commits up to an Additional $2 Million for Longer-Term Rebuilding Efforts
Amgen Staff Disaster Relief Fund Deployed to Assist Puerto Rico-Based Staff
THOUSAND OAKS, Calif., Sept. 22, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in ...
Source: Amgen News Release - September 22, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New FOURIER Analysis Shows Repatha ® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
Data Supports Safety and Efficacy of Repatha in Patients With Diabetes
Simultaneously Presented at EASD 2017 and Published in The Lancet Diabetes & Endocrinology
THOUSAND OAKS, Calif., Sept. 15, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) significantly and consistently reduced cardiovascular events in patients with and without diabetes at baseline.
The analysis showed that diabetes was independently associated with a substa...
Source: Amgen News Release - September 15, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab)
First Ever Biosimilar to Fight Cancer Approved by FDA
THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI is approved for...
Source: Amgen News Release - September 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Thursday, Sept. 14, 2017, in London. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology...
Source: Amgen News Release - September 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
EVENITY ™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
EVENITY Followed by Alendronate Reduced the Incidence of New Vertebral, Clinical, Non-Vertebral and Hip Fractures Compared to Alendronate Alone
Additional Details on Observed Cardiovascular Safety Signal Provided
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral...
Source: Amgen News Release - September 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity
THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response assess...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Highlights The Latest EVENITY ™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
First Presentation of Detailed EVENITY ARCH Study Results and FRAME Extension Final Analysis
10-Year Data From Long-Term Prolia FREEDOM Study
THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® (denosumab) at this year's Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Denver from Sept. 8-11, 2017.
"The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific understanding and care...
Source: Amgen News Release - September 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Data Demonstrate Aimovig ™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Aimovig Reduced Monthly Migraine Days for Patients With Chronic Migraine and Prior Treatment Failure, a Population With Significant Unmet Need
Results From New Dedicated Cardiovascular Study Support Overall Safety Profile Observed in Aimovig Clinical Study Program
Aimovig is the Only Investigational Biologic Product Specifically Designed to Prevent Migraine by Blocking the CGRP Receptor, Which is Associated With Migraine Activation
THOUSAND OAKS, Calif., Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimov...
Source: Amgen News Release - September 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Morgan Stanley Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 12, 2017, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from...
Source: Amgen News Release - September 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
Novel Investigational Drug is Designed to Block Thymic Stromal Lymphopoietin (TSLP) - An Upstream Driver of Inflammation in Asthma
Results Published Today in New England Journal of Medicine and to be Presented at European Respiratory Society (ERS) Congress Next Week
THOUSAND OAKS, Calif., Sept. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) today announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a novel anti-thymic stromal...
Source: Amgen News Release - September 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
